DT&CRO CO., Ltd. (KOSDAQ:383930)
2,490.00
-80.00 (-3.11%)
At close: Jan 29, 2026
DT&CRO CO. Revenue
DT&CRO CO. had revenue of 12.57B KRW in the quarter ending September 30, 2025, with 19.56% growth. This brings the company's revenue in the last twelve months to 44.36B, up 76.73% year-over-year. In the year 2024, DT&CRO CO. had annual revenue of 35.97B with 35.30% growth.
Revenue (ttm)
44.36B
Revenue Growth
+76.73%
P/S Ratio
0.70
Revenue / Employee
n/a
Employees
n/a
Market Cap
31.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35.97B | 9.38B | 35.30% |
| Dec 31, 2023 | 26.59B | -17.42B | -39.59% |
| Dec 31, 2022 | 44.01B | 11.26B | 34.38% |
| Dec 31, 2021 | 32.75B | 12.66B | 63.02% |
| Dec 31, 2020 | 20.09B | 9.50B | 89.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LabGenomics | 89.36B |
| HLB bioStep | 71.47B |
| C&R Research | 63.97B |
| DreamCIS | 62.06B |
| WOOJUNG BIO | 37.12B |
| P&K Skin Research Center | 22.13B |
| BioInfra | 21.92B |
| Hyundai ADM Bio | 9.74B |